New appointments strengthen bone and joint research
The chance of relief from common but crippling forms of joint diseases such as arthritis and osteoporosis has been boosted with the establishment of a second Chair in the field of rheumatology at the University of Sydney.
Arthritis specialist and Professor of Medicine David Hunter, has been appointed Florance and Cope Chair of Rheumatology while fellow joint and bone expert Professor Lyn March will assume the role of the newly formed Liggins Chair of Rheumatology and Musculoskeletal Epidemiology. The Florance and Cope Chair of Rheumatology was formed almost 30 years ago and has been instrumental in advancing research and education in musculoskeletal sciences.
While Professor Hunter’s work has been focussed on clinical and translational research in osteoarthritis, Professor March has been conducting clinical trials in fish oil, glucosamine and stem cells for osteoarthritis and leading an international group measuring the global burden of musculoskeletal disorders. Both will be based at the University’s Northern Clinical School within the Royal North Shore Hospital and will build upon the established research strengths of the campus which is internationally recognised for its expertise in musculoskeletal sciences.
Dean of the Sydney Medical School, Professor Bruce Robinson said “We have found two exceptional clinical leaders who will sustain and build on our established strengths and ensure that Sydney Medical School remains at the forefront of bone and joint research. “
“Professor David Hunter and Professor Lyn March are both clinicians as well as highly recognised researchers, only too well aware of the burden of arthritis and other musculoskeletal conditions on individuals and their families.”
“We are extremely grateful for the support of Arthritis Australia, which has provided funding for the Florance and Cope Chair and for the funds from the Liggins Bequest to the University of Sydney.”
“The funds have allowed us to create an additional chair position. Both Chairs will provide leadership through original, innovative and distinguished research, teaching and curriculum development, and professional training of medical students and registrars,” he said.
CEO of Arthritis Australia, Ainslie Cahill said her organisation’s vision is to radically restrict the rate of growth of arthritis in Australia and to be a leader in funding and advocating world-class research.
“In Australia nearly one in five people has arthritis. Many people think arthritis is a normal part of getting older. This is not true. In fact two out of every three people with arthritis are between 15 and 60 years old. Arthritis can affect people from all backgrounds, ages and lifestyles.”
Sydney Medical School
Beth Quinlivan, Director of Marketing
+61 2 9036 6528 or +61 412 416 895
Ainslie Cahill, CEO
+61 2 9518 4441 or +61 407 661 023